Cytox is a precision medicine company with a focus on neurodegenerative disorders such as Alzheimer’s disease. The Cytox scientific and proprietary technology platform is being applied to the prediction of cognitive decline and neurodegenerative disorder risk.
The Mayo Clinic is an integrated clinical practice, education and research institution specializing in treating patients. It hosts the USA national “All of Us” biobank as well as its own biobank resources.
Thermo Fisher Scientific is a very well-resourced company with products and services that aim to serve the Life Science community. It has approximately 70,000 employees globally.
AKESOgen is a biomarker, genomics, pharmacogenomics and biobanking contract research organisation (CRO) that serves the academic, pharmaceutical, biotechnological, and agricultural industries.
The US 2018 Omnibus Budget Bill includes $414 million in new funding for Alzheimer’s disease research which represents a 30% increase.
Focused on Alzheimer’s Cytox has entered into a research collaboration with the Mayo Clinic to develop new proprietary algorithms for the early diagnosis and prognosis of Alzheimer’s.
Given recent advances in the understanding of Alzheimer’s risk, Cytox plans to use Mayo Clinic resources to benchmark its current prediction algorithm which makes use of the Thermo Fisher Scientific Applied Biosystems™ GeneTitan™ Multi-Channel (MC) instrument platform.
The Mayo Clinic’s Alzheimer’s Disease Research Center will provide biobank samples from research participants classified as clinically normal, diagnosed with mild cognitive impairment and diagnosed with mild Alzheimer’s disease with associated amyloid PET imaging data. Genotyping of DNA samples will be performed by AKESOgen.
“The Mayo Clinic Alzheimer’s biobank presents a tremendous research opportunity, not only due to the thousands of blood samples it holds, but also because of the clinical annotation accompanying the samples.” … “By working closely with Mayo Clinic and its researchers, we hope to further validate the performance of our current approaches for assessing genetic risk for developing Alzheimer’s disease, and develop new, more targeted, precision-based methods”. Dr Richard Pither, CEO of Cytox.